Johnson & Johnson announced on Tuesday that its one-shot COVID-19 vaccine has performed well in real-world studies, offers long-lasting protection against the virus and boosts the immune system when given as a booster.
Sept.21 (UPI) — Johnson & Johnson announced on Tuesday that its one-shot COVID-19 vaccine has performed well in real-world studies, offers long-lasting protection against the virus and boosts the immune system when administered as a booster a few months after the original dose. The pharma company made the announcement in a release of late-stage clinical data for the adenovirus-based vaccine, produced by Johnson & Johnson subsidiary Janssen, which was given emergency use authorization in the United States early this year. Johnson & Johnson said it performed two studies in which volunteers received a second vaccine dose between two and six months after the first.
